Abstract
AbstractBackgroundEpidemiological studies suggest that L‐type calcium channel (LTCC) antagonists may reduce the incidence of neurodegenerative diseases including Alzheimer’s disease (AD). However, the neuroprotective mechanism of LTCC antagonists is unknown. Amyloid‐β (aβ) increases intracellular calcium signaling, which regulates lysosomal processing and microglial inflammatory responses, both of which are altered in AD. Neurons near aβ plaques develop dystrophic neurites, which are abnormal axonal swellings that accumulate lysosomes. Further, microglia accumulate around aβ plaques and secrete inflammatory cytokines. We hypothesized that antagonism of LTCCs with isradipine would reduce aβ plaque associated dystrophic neurites and inflammatory microglia in the 5XFAD mouse model of AD by restoring normal intracellular calcium regulation.MethodWe treated 6‐ and 9‐month‐old 5XFAD mice with isradipine (3 mg/kg/day) or vehicle via subcutaneous pellets for 30 days. Following three weeks of treatment we tested locomotion and cognitive behavior via open field, novel object recognition and Morris water maze. We measured gene expression of inflammatory mediators (IL1β, TNF, CD68) and LTCC subunits (Cav1.2, Cav1.3) using qPCR. Using immunohistochemistry (IHC), we examined aβ plaque number and area (D54D2 and ThioS), microglia area (Iba1), dystrophic neurites area and particle number (LAMP1) normalized to total brain area.ResultIHC revealed that isradipine treatment in 9‐month‐old 5XFADs decreased the total area of LAMP1 positive dystrophic neurites (p = 0.0310) compared to vehicle‐treated 5XFADs; this change was not observed in the 6‐month‐old group. Isradipine treatment in the 9‐month‐old 5XFADs also led to a decreasing trend (p = 0.0552) in plaque load compared to vehicle‐treated 5xFADs as measured by IHC. Isradipine treatment did not modulate plaque associated microglia as measured by IHC or inflammatory gene expression as measured by qPCR, regardless of age. There was no treatment effect on behavior or expression of LTCC subunits.ConclusionOur data show that isradipine reduces aβ plaque associated dystrophic neurite pathology in 9‐month‐old 5XFAD mice, potentially showing LTCC play a role in mediating this specific phenotype. Our future studies will focus on understanding why antagonizing LTCCs leads to a decrease in LAMP1 and whether this is due to changes in lysosomal development and processing or other possible mechanisms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.